Literature DB >> 19492438

Distinct interactions of 2'- and 3'-O-(N-methyl)anthraniloyl-isomers of ATP and GTP with the adenylyl cyclase toxin of Bacillus anthracis, edema factor.

Srividya Suryanarayana1, Jenna L Wang, Mark Richter, Yuequan Shen, Wei-Jen Tang, Gerald H Lushington, Roland Seifert.   

Abstract

Anthrax disease is caused by the spore-forming bacterium, Bacillus anthracis. B. anthracis produces a calmodulin-activated adenylyl cyclase (AC) toxin, edema factor (EF). Through excessive cAMP accumulation EF disrupts host defence. In a recent study [Taha HM, Schmidt J, Göttle M, Suryanarayana S, Shen Y, Tang WJ, et al. Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides. Mol Pharmacol 2009;75:693-703] we showed that various 2'(3')-O-N-(methyl)anthraniloyl (MANT)-substituted nucleoside 5'-triphosphates are potent inhibitors (K(i) values in the 0.1-5 microM range) of purified EF. Upon interaction with calmodulin we observed efficient fluorescence resonance energy transfer (FRET) between tryptophan and tyrosine residues of EF and the MANT-group of MANT-ATP. Molecular modelling suggested that both the 2'- and 3'-MANT-isomers can bind to EF. The aim of the present study was to examine the effects of defined 2'- and 3'-MANT-isomers of ATP and GTP on EF. 3'-MANT-2'-deoxy-ATP inhibited EF more potently than 2'-MANT-3'-deoxy-ATP, whereas the opposite was the case for the corresponding GTP analogs. Calmodulin-dependent direct MANT fluorescence and FRET was much larger with 2'-MANT-3'-deoxy-ATP and 2'-MANT-3'-deoxy-GTP compared to the corresponding 3'-MANT-2'-deoxy-isomers and the 2'(3')-racemates. K(i) values of MANT-nucleotides for inhibition of catalysis correlated with K(d) values of MANT-nucleotides in FRET studies. Molecular modelling indicated different positioning of the MANT-group in 2'-MANT-3'-deoxy-ATP/GTP and 3'-MANT-2'-deoxy-ATP/GTP bound to EF. Collectively, EF interacts differentially with 2'- and 3'-MANT-isomers of ATP and GTP, indicative for conformational flexibility of the catalytic site and offering a novel approach for the development of potent and selective EF inhibitors. Moreover, our present study may serve as a general model of how to use MANT-nucleotide isomers for the analysis of the molecular mechanisms of nucleotide/protein interactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19492438      PMCID: PMC2762704          DOI: 10.1016/j.bcp.2009.04.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  19 in total

1.  Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins.

Authors:  Yuequan Shen; Young-Sam Lee; Sandriyana Soelaiman; Pamela Bergson; Dan Lu; Alice Chen; Kathy Beckingham; Zenon Grabarek; Milan Mrksich; Wei-Jen Tang
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

2.  Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides.

Authors:  Hesham M Taha; Jennifer Schmidt; Martin Göttle; Srividya Suryanarayana; Yuequan Shen; Wei-Jen Tang; Andreas Gille; Jens Geduhn; Burkhard König; Stefan Dove; Roland Seifert
Journal:  Mol Pharmacol       Date:  2008-12-04       Impact factor: 4.436

3.  Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin.

Authors:  Chester L Drum; Shui-Zhong Yan; Joel Bard; Yue-Quan Shen; Dan Lu; Sandriyana Soelaiman; Zenon Grabarek; Andrew Bohm; Wei-Jen Tang
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

Review 4.  Fluorescent nucleotide analogs: synthesis and applications.

Authors:  D M Jameson; J F Eccleston
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

5.  Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2 '(3')-O-(N-Methylanthraniloyl)-guanosine 5 '-triphosphate.

Authors:  Tung-Chung Mou; Andreas Gille; David A Fancy; Roland Seifert; Stephen R Sprang
Journal:  J Biol Chem       Date:  2004-12-09       Impact factor: 5.157

6.  Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'-substituted purine- and pyrimidine nucleotide inhibitors.

Authors:  Tung-Chung Mou; Andreas Gille; Srividya Suryanarayana; Mark Richter; Roland Seifert; Stephen R Sprang
Journal:  Mol Pharmacol       Date:  2006-06-09       Impact factor: 4.436

Review 7.  The structure and function of novel proteins of Bacillus anthracis and other spore-forming bacteria: development of novel prophylactic and therapeutic agents.

Authors:  Mark J Jedrzejas
Journal:  Crit Rev Biochem Mol Biol       Date:  2002       Impact factor: 8.250

8.  A fluorimetric assay for real-time monitoring of adenylyl cyclase activity based on terbium norfloxacin.

Authors:  Corinna M Spangler; Christian Spangler; Martin Göttle; Yuequan Shen; Wei-Jen Tang; Roland Seifert; Michael Schäferling
Journal:  Anal Biochem       Date:  2008-06-13       Impact factor: 3.365

9.  Molecular analysis of the interaction of Bordetella pertussis adenylyl cyclase with fluorescent nucleotides.

Authors:  Martin Göttle; Stefan Dove; Phillip Steindel; Yuequan Shen; Wei-Jen Tang; Jens Geduhn; Burkhard König; Roland Seifert
Journal:  Mol Pharmacol       Date:  2007-06-06       Impact factor: 4.436

10.  Characterization of mouse heart adenylyl cyclase.

Authors:  Martin Göttle; Jens Geduhn; Burkhard König; Andreas Gille; Klaus Höcherl; Roland Seifert
Journal:  J Pharmacol Exp Ther       Date:  2009-03-23       Impact factor: 4.030

View more
  6 in total

1.  Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases.

Authors:  Cibele Pinto; Gerald H Lushington; Mark Richter; Andreas Gille; Jens Geduhn; Burkhard König; Tung-Chung Mou; Stephen R Sprang; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2011-05-18       Impact factor: 5.858

Review 2.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 3.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

4.  Bis-halogen-anthraniloyl-substituted nucleoside 5'-triphosphates as potent and selective inhibitors of Bordetella pertussis adenylyl cyclase toxin.

Authors:  Jens Geduhn; Stefan Dove; Yuequan Shen; Wei-Jen Tang; Burkhard König; Roland Seifert
Journal:  J Pharmacol Exp Ther       Date:  2010-10-20       Impact factor: 4.030

5.  Synthesis and evaluation of fluorescent cap analogues for mRNA labelling.

Authors:  Marcin Ziemniak; Mariusz Szabelski; Maciej Lukaszewicz; Anna Nowicka; Edward Darzynkiewicz; Robert E Rhoads; Zbigniew Wieczorek; Jacek Jemielity
Journal:  RSC Adv       Date:  2013       Impact factor: 3.361

Review 6.  Structural Biology and Molecular Modeling to Analyze the Entry of Bacterial Toxins and Virulence Factors into Host Cells.

Authors:  Irène Pitard; Thérèse E Malliavin
Journal:  Toxins (Basel)       Date:  2019-06-24       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.